Empagliflozin (sold under the brand name Jardiance) may reduce major adverse kidney events in some type 2 diabetes patients better than other medications, researchers say. The study used U.S. Department of Veterans Affairs (VA) data to assess the effectiveness of empagliflozin versus other antihyperglycemic drugs. Read more